Pharmaceutical Trade and Supply Chain Survey - Q1 2020: Coronavirus Disease 2019 (COVID-19) Sector Impact
Summary
The Coronavirus Disease 2019 (COVID-19) Sector Impact: Pharmaceutical Trade and Supply Chain Survey - Q1 2020 provides in-house analyst expertise on the results of a 5 minute survey of 13. The publisher's Pharma clients and prospects, which was fielded from March 13, 2020 to March 24, 2020.
Scope
Reasons to Buy
Objectives included -
Summary
The Coronavirus Disease 2019 (COVID-19) Sector Impact: Pharmaceutical Trade and Supply Chain Survey - Q1 2020 provides in-house analyst expertise on the results of a 5 minute survey of 13. The publisher's Pharma clients and prospects, which was fielded from March 13, 2020 to March 24, 2020.
Scope
- This report provides an assessment of how the pharmaceutical industry perceives the supply chain disruption caused by the COVID-19 pandemic, including the challenges associated with clinical trials, logistics, API and finished dose manufacturing.
- Since the first case was diagnosed in Wuhan, China, in December 2019, COVID-19 cases have continued to rise rapidly across the globe.
Reasons to Buy
Objectives included -
- Benchmark companies’ primary concerns
- Determine the impact of COVID-19 to date on supply chains
- Assess companies’ strategic future plans
- Track changes to corporate strategy and attitudes
Table of Contents
1 Study Design2 Primary Business Concerns
3 Impact of COVID-19 on Company Revenue
4 Dedicated Planning Team
5 Supply Chain Concerns
6 Clinical Trial Concerns
7 Planning Scenarios
8 Summary
9 Appendix
